Press Release Source: Northwest Biotherapeutics
Northwest Biotherapeutics to Present Update on Brain Cancer Clinical Data at the Cambridge Healthtech Institute's Cancer Immunotherapeutics and Vaccines Conference
Monday August 21, 8:00 am ET
Personalized Vaccine Continues to Yield Unprecedented Long-term Survival in Glioblastoma Multiforme Patients
BOTHELL, Wash., Aug. 21 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics (OTCBB: NWBT.OB - News) today announced that the company will be presenting an update on NWBT's lead product candidate, DCVax®-Brain for Glioblastoma multiforme (GBM), at the Cambridge Healthtech Institute's (CHI) 3rd Annual Cancer Immunotherapeutics and Vaccines Conference, August 22nd-23rd at the Royal Sonesta Hotel in Cambridge, Massachusetts.
Company President Alton Boynton, Ph.D., will give an oral presentation during the Dendritic Cells session at the CHI conference at 10:45 AM EDT, Wednesday, August 23rd.
Dr. Boynton will describe the Phase I survival and progression data on patients who have received DCVax®-Brain, a therapeutic personalized cancer vaccine.
Dr. Boynton will be available to discuss the findings and the planned commercial development of DCVax®-Brain as a highly promising new cancer therapy for most cancers.
The Company's two Phase I clinical trials of DCVax®-Brain involved patients with GBM, the most lethal form of brain cancer.
Dendritic cell-based immunotherapy, such as NWBT's DCVax®-Brain vaccine, uses autologous dendritic cells that are pulsed with tumor biomarkers (antigens).
This therapeutic approach aims at safely stimulating anti-tumor immune responses to prevent tumor recurrence or progression.
The two Phase I clinical trials were carried out at University of California, Los Angeles (UCLA) under the direction of Linda Liau, M.D., Ph.D., Associate Professor of Neurosurgery and Director of the Malignant Brain Tumor Program at the UCLA School of Medicine.
Dr. Liau will serve as Principal Investigator for the upcoming Phase II trial.
Details about the ongoing, long-term survival data from the second Phase I trial will be presented.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell based vaccines, and therapeutic antibodies. The Company's three lead product candidates are: DCVax®-Brain, a personalized dendritic cell vaccine for treatment of newly diagnosed Glioblastoma multiforme, which is entering a large Phase II clinical trial; DCVax®-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer, which is entering a Phase III clinical trial; and CXCR4 a therapeutic monoclonal antibody for treatment of solid tumors, that is in late preclinical development.
biz.yahoo.com
regards,
John |
